The guidelines suggest the option of using a less-invasive initial test including endoscopic ultrasonography (EUS) or magnetic resonance cholangiopancreatography (MRCP) in patients with intermediate probability of CL (2). However, there is a paucity of published literature supporting this recommendation. Furthermore, in the study by Adams et al. (3) such a recommendation is not supported by their data. Additionally, because the prevalence of CL varies among ethnic groups, we did not consider performing pre-ERCP (endoscopic retrograde cholangiopancreatography) imaging studies in our study.
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We speculate that if we had performed pre-ERCP imaging (EUS or MRCP), the accuracy of the guidelines would have improved from 41% to ~60% in this intermediate-probability subgroup. This was implied by analyzing those patients in our database with an intermediate and high probability of CL, the latter based solely on the presence of a common bile duct (CBD) stone on abdominal ultrasound (Table I ). These patients with the presence of a CBD stone on ultrasound that did not fulfill any of the other high-probability criteria had a 61% probability of CL. Thus, even if we had used pre-ERCP imaging studies in the intermediate-probability subgroup, the rate of unnecessary ERCPs would probably continue to be unacceptably high (~40%) and even at a higher cost.
In this subgroup of patients, the cholecystectomy and intraoperative cholangiography (IOC) is a better diagnostic and therapeutic approach (4). Therefore, based on ERCP expertise the performance of cholecystectomy and IOC is a reasonable approach, so ERCP is performed postoperatively when the IOC is positive for CL or if needed for other complications (e.g., bile leak, duct injury) (5). and those with high-probability, the latter determined only for the presence of a CBD stone on the US (excluding those with either clinical ascending cholangitis, bilirubin > 4 mg/dL or the combination of the strong predictors, bilirubin level 1.8-4 mg/ dL + CBD on US > 6 mm).
